Dr. Michael Lutz
(CEO, LifeCodexx AG)
Early 2014 cytena appointed Dr. Michael Lutz, an experienced biotech entrepreneur, as advisor for strategic and business planning . Dr. Lutz has extensive experience in the development and management of biotech companies. Since 2005, Dr. Lutz has successfully built up six biotech companies and raised funding well over 10 million EUR. Three of these companies were sold to publicly traded biotech companies. His current focus is in the area of prenatal diagnosis where he acts as CEO of LifeCodexx AG since 2010. Before 2005 Dr. Lutz spent many years working in various management positions at Novartis Pharma and Evotec.
Dr. Rainer Wessel
(Founder and Managing Partner at MIM-Deutschland GmbH)
Dr. Wessel has more than 20 years of experience in the pharmaceutical and life science industry. He served for 5 years as Director Cluster-Management at the Rhine-Main Leading Edge Immunology Cluster Ci3 and 9 years as Chief Executive Officer of biotechnology companies Ganymed Pharmaceuticals AG (Mainz) and Axxima Pharmaceuticals AG (Munich). Before, he served as International Head of IP & Licensing at Qiagen GmbH (Hilden). Dr. Wessel was trained in Intellectual Property at the patent department of Boehringer Ingelheim (BI) GmbH (Ingelheim) after a research trainee position at BI KK (Osaka, Japan). The BI Fonds and DAAD fellow received his PhD from the University of Constance in 1992.
Among other functions, Dr. Wessel is Supervisory Board member of the International Council of the Life Sciences (ICLS, Washington, DC), a member of the Development Board of the German Cancer Research Center (DKFZ, Heidelberg), the International Strategy Board of Oncotyrol (Innsbruck) and the International Institute of Strategic Studies (IISS, London, UK). From 2004 – 2015 he served as a Board Member of the German biotech industry organization BIO Deutschland (Berlin).
Prof. Dr. med. Christof von Kalle
(Director of the Departement of Translational Oncology, NCT and DKFZ, Heidelberg)
Professor Christof von Kalle has been director of the Department of Translational Oncology at NCT and DKFZ since July 2005, chairing the NCT Board of Directors. As a physician scientist, with a clinical background in hematology/oncology, Prof. von Kalle is an internationally renowned scientific leader in stem-cell research, mutation analysis, and gene transfer, with >150 high-impact publications. He is an elected member of the European Academy of Cancer Sciences and serves as chair of the CCC Network of German Cancer Aid. Prof. von Kalle coordinates overall NCT activities, with the primary goal of facilitating excellence in translational and clinical research. The department is home to internationally renowned research groups for stem-cell research, applied functional genomics, lymphoma research, molecular diagnostics, and gene therapy. Physician scientists are involved in clinical activities, patient care and innovative clinical trials. The department oversees NCT POP, providing individual patient treatment based on in-depth molecular analysis.
Prof. Dr. Roland Zengerle
(Institute for Microsystems Technology, University Freiburg)
Prof. Dr. Roland Zengerle is full professor at the Department of Microsystems Engineering at the University of Freiburg and director at the "Institut für Mikro- und Informationstechnik" of the Hahn-Schickard-Gesellschaft (HSG-IMIT). The research of Dr. Zengerle is focused on microfluidics and specialises in Lab-on-a-Chip systems, contact-free microdosage technologies, medical MEMS, bio fuel cells as well as microfluidics in nanoporous media. Dr. Zengerle co-authored more than 250 papers. He is editor of the Springer Journal of Microfluidics and Nanofluidics and a member of the German national academy of sciences, Leopoldina.